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After publication of the article \[[@CR1]\], the author reported that this article contained some errors.

The photograph of sh-NC in Fig. [1](#Fig1){ref-type="fig"}c was misplaced. The correct version of the figure and the figure legend is presented below.Fig. 1Prognostic value of miR-30d expression in PCa patients and its functions on tumor growth and angiogenesis in vivo using LNCaP cell induced tumor xenografts. **a** Kaplan-Meier analyses of biochemical recurrence (BCR)-free survival and overall survival of PCa patients based on miR- 30d expression in Taylor and TCGA datasets. **b** LNCaP cells stably expressing miR-30d formed significantly larger tumor nodules and remarkably speeded up tumor xenografts growth compared with the controls. Conversely, PCa cells that permanently suppressed miR-30d expression led to the smaller tumor nodules and the slower tumor growth compared with the control. **c** Immunohistochemical analysis using pan-endothelial marker CD31 antibody. **d** VEGFA protein expression in different groups detected by Western blot analysis. Data were presented as Mean ± SD. \**P* \< 0.05. \*\**P* \< 0.01
